Health care costs of home care enzyme replacement therapy for patients with lysosomal storage diseases in Germany
As total costs are almost entirely driven by infusion-related material, especially the ERT drug, moving ERT into the home environment is not expected to increase costs.
Authors
- Tonio Schoenfelder (ORCID: https://orcid.org/0000-0001-6158-4191)
- Ria Heinrich (ORCID: https://orcid.org/0000-0002-0542-5580)
- Franziska Claus (ORCID: https://orcid.org/0009-0003-7670-5613)
Institutions
- Mayo Clinic Health System (US)
- Technische Universität Dresden (DE)
Publication Details
- Journal
- Orphanet Journal of Rare Diseases
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1186/s13023-024-03492-4
- Citations
- 4
- Primary Topic
- Lysosomal Storage Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 1.31
Funders
- Sanofi
- Sanofi-Aventis Deutschland